

OFFICIAL

This facsimile message and its contents are legally privileged and confidential information intended solely for the use of the addressee. If the reader of this message is not the intended recipient, you are hereby notified that any dissemination, distribution, copying or other use of this message and its contents is strictly prohibited. If you have received this telecopy in error, please notify us immediately by telephone and return the original message to us at the address shown below via the Postal Service. Thank You.

ALSTON & BIRD LLP

3201 Beechleaf Court, Suite 600
Raleigh, NC 27604-1062

919-862-2200
Fax: 919-862-2260

FAX RECEIVED

FEB 15 2002

GROUP 1600**TELECOPY****PLEASE DELIVER AS SOON AS POSSIBLE**

DATE: February 14, 2002

TO: Hope Robinson

FROM: Leslie T. Henry

Per your request, we are resending the attached Supplement Amendment After Final Action to
(703) 308-4242.

Thank you.

*Please
#15702*

NO. OF PAGES:
(Including cover page)

3

OPERATOR: SD 3-16071**IF NOT RECEIVED PROPERLY, PLEASE NOTIFY ME IMMEDIATELY AT**

USER CODE: pixll

FAX NUMBER:

703 308 4242

CLIENT/MATTER: 35784/205462

REQUESTED BY: Lynda Pixley 2233

VOICE NUMBER:

OFFICIAL #27EAttorney's Docket No. 1543.004 (5784-81)PATENT**RESPONSE UNDER 37 C.F.R. 1.116 - EXPEDITED
PROCEDURE - EXAMINING GROUP 1653****IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re:	Whitehouse	Confirmation No.:	None assigned
Appl. No.:	09/385,114	Group Art Unit:	1653
Filed:	August 27, 1999	Examiner:	H. Robinson
For:	ANGIOGENICALLY EFFECTIVE UNIT DOSE OF FGF-2 AND METHOD OF USE		

February 14, 2002

BOX AF
Commissioner for Patents
Washington, DC 20231

**SUPPLEMENTAL AMENDMENT AFTER FINAL ACTION
PURSUANT TO 37 C.F.R. § 1.116**

Sir:

Responsive to the telephone conversation with the Examiner on February 14, 2002, and supplemental to the Amendment filed January 7, 2002, in response to the Final Office Action of September 7, 2001, Applicants respectfully request the Examiner to enter the following amendment into the above-identified application.

In the Sequence Listing:

On page 1 of the paper copy of the Sequence Listing, in the first field reporting priority document data (first field <150> and <151>), please delete the information relating to U.S. Provisional Application Serial No. 60/145,743 and its respective filing date of 1998-09-03.

REMARKS

During the preparation of the Sequence Listing for the above-identified application, U.S. Provisional Application Serial No. 60/145,743 was included in the priority document data in error. Applicant wishes to thank the Examiner for identifying this error in the Sequence Listing.